InvestorsHub Logo
Followers 3
Posts 296
Boards Moderated 0
Alias Born 12/21/2022

Re: None

Monday, 05/08/2023 7:51:23 PM

Monday, May 08, 2023 7:51:23 PM

Post# of 575
Guess, no new responses in APTIVATE Phase 1/2 clinical trial where they are using a therapeutic dose of Tusp as mono, although first patient was dosed on Jan 30, 2023 and as they say, "patients were accrued rapidly". Keep in mind that majority of CRs was observed in cycle 1. Are they enrolling mostly Flt3i failures and p53 mut patients?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent APTO News